LBPMedicine(SH:688393) Sou Hu Cai Jing·2025-08-14 13:56Group 1 - The core viewpoint of the article highlights that Anbiping's stock price closed at 29.63 yuan, down 3.52%, with a rolling PE ratio of 1239.07 times, significantly higher than the industry average of 55.76 times [1] - Anbiping's total market capitalization is reported at 2.772 billion yuan, ranking 122nd in the medical device industry based on PE ratio [1] - As of March 31, 2025, Anbiping has 10,309 shareholders, an increase of 4,393 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Anbiping's main business focuses on tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] - The latest quarterly report for Q1 2025 shows that the company achieved operating revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1] - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, indicating that Anbiping's valuation is significantly above industry standards [2]